reason report
use data transform pharma servic initi op pt
bottom line initi coverag inc
outperform rate price target per share
posit stock compani sever reason first
vast array technolog solut servic possibl
thorough extens set de-identifi data world
technolog solut data asset make invalu
pharmaceut biotech industri secondli pharmaceut
market continu grow healthi rapid rate margin
pharmaceut manufactur higher healthcar sub-
sector industri continu increas spend organ
growth in-sel opportun vendor space
high also view combin quintil im win
deal manufactur streamlin vendor relationship
im data solut use part bid process
win new cro project lastli like manag consist
beaten revenu earn expect sinc
judgment merg quintil seem sound
initi coverag op pt
pharma growth market one main reason
posit natur market compani
sell pharma industri grow
percent sale continu rise number drug phase
phase trial continu increas number compani
activ pipelin also increas furthermor oper margin
biotech pharma higher sub-sector within healthcar
lot specul drug price reform
believ pharma continu find way increas profit
bring new drug market firm like help
reduc time cost take bring drug effect market
new technolog seem work impress
manag creat new oce orchestr custom
engag product effect compet veeva
well-establish domin market share posit
surpris oce new account far includ
larg custom one seat consid
firm like mdso coincid view
compani serv pharma stock perform well
past year market larg enough view support
mdso growth
net debt total capit
price-to-earnings lt ep growth
ep
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm
ep exclud stock comp restructur transact one-tim item
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rx trend deriv im health
unmatch data capabl give competit edg one
key strength legaci im platform solut
make one-third technolog analyt divis
view core long-term asset firm
non-identifi patient record data feed
data supplier accord medacorp specialist check
im data one trust sourc data world
use nearli pharma life scienc compani assess
perform drug market even competitor
use im data conjunct solut
believ own data abl effect bring
technolog solut market rapid
quintil technolog solut win combin
view combin im quintil make lot sens
pharma manufactur pick cro want work
believ access im data iqv suit technolog
consult servic huge competit advantag addit
work manufactur get clinic trial done
also use vast data technolog consult capabl
advis launch strategi time merger equal
view skeptic appear like deal work
continu work organ revenu growth
 divis increas y/i well ahead first
three quarter growth ltm net new contract servic
increas y/i ad new client
quintil transact work well view revenu
growth within acceler
manag judgment impress
qualiti leadership team sinc beaten
consensu revenu ebitda ep expect everi singl quarter
cours manag rais guidanc year
consist like manag investor expect well
believ lead steadi stock perform durabl price-to-earnings
multipl also impress actual outcom quintil
transact gener impress iqv deal valu
creativ reflect well manag judgment
initi coverag outperform believ share
pois outperform market next month
enter post-transact quintil begin see
 top-lin growth acceler also believ oce solut
continu gain traction sinc tightli correl
legaci im data also optimist contract sale medic
solut start improv oper
revenu ep estim slightli ahead consensu
pt base ep multipl
high rel histori believ well deserv
initi coverag inc outperform rate
price target iqvia previous known quintilesim form follow
merger quintil im health iqvia offer cover broad section
healthcar landscap primari focu life scienc servic technolog well
clinic research one largest contract research organ cro world
iqvia forefront technolog innov drug develop healthcar
industri offer rang research develop applic real world
analyt outcom commerci technolog iqvia captur signific
portion market drive toward digit healthcar iqvia
improv overal effici system also creat vast databas de-identifi
data use continu drive industri forward data improv
analyt iqvia work maxim effici clinic trial smart process
inform drive better quicker result allow product enter system way
benefit manufactur well patient larg cro extens technolog
data analyt capabl believ combin solut quintil im creat highli
attract platform manufactur embrac leader industri expect
iqvia continu drive innov improv outcom util data
asset technolog innov rate share outperform price target
inc lead provid analyt technolog contract research
global life scienc industri compani form merger im health
quintil conclud octob combin compani leverag analyt rigor
clariti data scienc enabl compani reimagin way oper
develop new approach clinic develop commerci speed innov
acceler improv healthcar human data scienc compani deliv
action insight intersect large-scal analyt technolog domain expertis
ia coretm furthermor deliv data analyt capabl assist biotech
medic devic pharmaceut compani govern agenc payer
stakehold healthcar system help develop deeper understand issu
within market million comprehens longitudin non-identifi patient
record iqvia one largest comprehens collect healthcar
inform global collect includ sale prescript promot data claim
electron medic record genom social media petabyt data petabyt
million gigabyt sourc supplier cover million data feed
throughout world data allow iqvia deliv insight technolog analyt
custom cover world pharmaceut term sale
background compani offer
iqvia develop clinic commerci capabl custom
proprietari inform advanc analyt transform technolog domain
expertis allow establish grow relationship stakehold throughout
life scienc valu chain extens list capabl includ
lead infrastructur believ one largest sophist
healthcar industri receiv nearli billion healthcar record annual
infrastructur connect data maintain proper oversight measur includ
privaci secur oper legal contractu protect
improv clinic trial design site identif patient recruit analytics-
driven clinic develop empow therapeut scientif domain specialist
vast level inform includ product track treatment inform
outcom million non-identifi patient global
robust real-world insight ecosystem enabl compani address critic
issu healthcar system includ cost valu outcom
retrospect databas analyt real-world data collect technolog platform
scientif expertis compani abl focu root caus issu identifi
way best mitig
grow set proprietari applic applic aim clinic
commerci area help client improv clinic oper perform achiev
maintain regulatori complianc adher orchestr sale oper
manag multi-channel market perform manag
global employe technolog analyt solut
research develop solut contract sale medic solut
iqvia coretm integr inform analyt technolog domain expertis
allow iqvia custom benefit effect option come
address research develop need commerci innov
breakthrough like virtual trial global real world evid network
iqvia portfolio focus four import decis make process
iqvia continu develop softwar servic applic expand level integr
allow client enhanc autom mani compon four key process
research develop
research develop process focus wide number task compani
provid custom assist overal market opportun assess well
project manag clinic monitor clinic trial support servic patient recruit
clinic trial laboratori servic strateg clinic trial plan design given increas
innov recent believ demand assist earli research
develop stage crucial iqvia custom help save cost line
improv certainti go/no go decis potenti elimin futur cost avoid
wast money fail trial could prevent furthermor throughout
develop stage drug go clinic trial iqvia help cost
effici trial util databas servic determin best
way proceed move forward
follow research develop stage pre-launch stage requir signific
commit second decis make process iqvia busi model abl
assist custom number task includ drug price optim launch
readi commerci plan brand posit messag test influenc network
territori design stage key determin best go-to-market strategi result
largest benefit custom plan drug launch requir signific market analysi
determin effici strategi iqvia custom abl leverag expertis
data construct strategi result success launch possibl base
year data million data point
iqvia help custom analyz market commerci readi perform health
contract sale forc hold observ studi drive stakehold engag step
key success launch proper team knowledg requir succeed
establish sale team access market accur forecast effici alloc
resourc critic success iqvia assist level differ maker
ensur forecast market analysi accur well ensur custom return
invest invest heavili develop product
final last decis make process product market iqvia assist
commerci oper ensur sale forc effect proper align multi-channel
market client relationship manag life-cycle manag process import
custom look continu drive maximum revenu newli introduc
product ensur maintain posit aggress market
iqvia breadth depth intellig address fundament question
iqvia believ drive forc valu proposit revolv around breadth
depth intellig provid client address fundament question
research develop
studi site target patient
enough patient clinic trial
long trial enrol take meet target patient volum
provid gener highest return repres busi
sale repres drive appropri prescrib
much pay sale repres next month
share patient appropri treat
underserv patient popul benefit new drug
brand gain enough market share quickli enough hit revenu forecast
like impact new therapi cost outcom
new therapi perform better exist standard care real-world
real-world data indic advers event detect clinic trial
iqvia broad client base
iqvia custom base includ pharmaceut biotechnolog devic diagnost
consum health compani claim nearli top pharmaceut
biotechnolog compani measur revenu custom mani subscrib
report servic mani differ countri custom iqvia serv includ
payer govern regulatori agenc provid pharmaceut distributor
pharmaci singl custom account revenu
share trade histor averag share seen strong run
past year compani earn multipl approach high level rel histori
high believ well deserv follow compani merger iqvia
continu grow cement leader healthcar technolog
clinic research space valuat may appear rel high compar five year
averag believ re-rat creat new normal compani continu
grow innov industri alway look new technolog drive effici
cost effect everi compani suppli chain well patient
believ iqv current valuat deserv see upsid move forward
share rel volatil past year amid gener turbul
stock market seen signific swing past year trade low
rang follow declin run current level
around recent all-tim high rang price movement
rather consider encourag upward momentum abil earn back
loss rel short amount time follow gener market sell-off
pressur stock believ iqvia upward price momentum well deserv given
firm abil continu drive revenu growth expect long-term upward momentum
continu propel stock forward
abil compet decemb introduc new platform
engag seem gain traction investor may believ
lock market believ market big enough grow fast enough
win share new account
includ roch mega-win seat view advantag
access actual im data use platform assess demand real-
quintil deal valu creativ investor may skeptic quintil
transact may skeptic firm abil realiz cost
revenu synergi revenu divis grew y/i organ
ad new client top lock
previous valu combin entiti seem reson well market
furthermor realiz two-third cost synergi compani
guid manag state revenu synergi growth would come
compani deliv date
abil innov integr grow legaci im data busi grow
slow rate even near flat believ excel track record bring
new product market drive growth custom engag compani current
work orchestr clinic trial solut come market soon
deploy machin learn artifici intellig wide array studi across
globe view proven track record develop deploy new solut
client base creat in-sel opportun growth
market demand investor may believ growth need eventu slow
may mani point solut dis-joint product view clinic
trial industri grow rapidli number product come market continu
increas overal industri grow organ top-lin constant currenc growth
view impress given fact revenu
lot discuss around drug price believ growth rate clinic trial
innov remain robust
strong grow end-market opportun
iqvia valu total market market consist outsourc research
develop real-world evid connect healthcar technolog enabl commerci
oper market focu life scienc broad healthcar industri within
market estim compani suggest total address market given
outsourc research develop biopharmaceut
spend iqvia estim total address opportun includ clinic
develop spend exclud preclin spend
compani estim approxim address outsourc opportun
real-world evid rwe connect iqvia manag estim
rwe connect health address market base sale
market opportun two equal part first total rwe market
tradit defin analyt platform implement medic
scientif analyt servic observ studi market access remain
address market come connect healthcar area includ
revenu cycl manag payer analyt technolog consult
technolog enabl commerci oper remain total market
includ area inform data wareh outsourc softwar
applic broad base servic market commerci servic
includ bucket includ recruit train salesforc deploy
consult brand commun advisori servic health inform analyt
three main area oper describ iqvia expos
total market revenu appear good start
great potenti expans ahead market continu grow consolid
identifi capit effici improv process save cost number
discuss deriv iqvia estim manag review third-parti
sourc estim forecast segment spend
trend drive demand
growth innov life scienc industri
iqvia estim global life scienc industri gener revenu
larg critic part global healthcar system base iqvia research manag
expect growth life scienc industri pharmaceut
emerg market expect increas compound-annual-growth-rate time
period emerg market becom import industri compani
becom increasingli import global sector iqvia expect organ
area continu appli high degre sophist emerg market commerci
oper accord pharma intellig seen strong increas total number
compani activ pipelin past year furthermor pharma intellig
show slight shift number compani space headquart locat
standpoint increas china rest apac
unit state europ seen modest declin percent total
figur total number compani activ pipelin increas
figur hq china rest apac increas percent total
growth research develop
iqvia highlight increas spend trend result multipl factor includ major
biopharma compani look replenish revenu patent cliff increas access
capit small mid-cap biotech compani recent increas approv regulatori
author iqvia estim new molecular entiti nme approv
compar suggest
continu expans industri given increas spend need effici
healthcar system iqvia expect continu creation opportun involv
compani chart see percentag sale pharma continu
grow percentag total sale increas expect
continu increas amount spend among pharmaceut compani
view strong benefit iqvia move forward
figur pharma revenu increas
increas complex
manag suggest biopharmaceut compani face increasingli difficult
environ improv standard care new type therapi biolog
genet target therapi gene stem cell therapi modal iqvia well
posit assist compani manag complex come new
highli regul environ iqvia coretm compani abl valid protocol
ensur studi new area greater accuraci enabl increas effici find
patient may diagnos predict analyt capabl iqvia
suggest abl understand epidemiolog physiolog differ
differ popul well abl conduct trial local certain geographi
key global growth compani look work multi-national well local
biopharmaceut compani assist new product innov especi certain area
asia emerg market global industri continu grow see grow number
drug pipelin increas densiti compani need focus way
best develop process ensur effici cost effect although past
two year number drug stage remain rel flat encourag see
strong growth number drug stage compani continu drive
figur number drug stage continu rise
financi pressur drive increas need effici
although industri grow consider iqvia see increas margin pressur
client result chang product mix price reimburs challeng
rise complianc cost develop compani look maxim product
lower cost across entir oper research develop commerci
oper like look compani like iqvia assist autom
vendor consolid new technolog host cloud base applic iqvia
help custom achiev simplifi process improv effici studi
tuft center studi drug develop estim all-in cost drug
approv climb nearli dollar signific increas
cost develop like one drive forc compani look outsid
vendor assist tuft studi date believ like
cost develop drug continu climb previou level view natur
increas cost reason end market client look compani
like iqvia assist product effici
figur bring drug market
tuft center studi drug develop
evolv need integr structur expand sourc data
iqvia end-market need access statist signific data organ abl
queri analyz differ type studi real-world evid longitudin
studi requir signific amount action data real-world evid studi need
aggreg integr larg data set across set therapi type patient
cohort longitudin studi need abil analyz non-identifi patient diagnos
treatment procedur laboratori test result order identifi proper patient
requir includ abil analyz social media activ order determin unmet
patient need support new drug relev inform span entir
healthcar spectrum differ level differ stakehold iqvia see opportun
broadli appli collect data structur organ integr storag
analyt solut data often unintegr unstructur silo
inconsist properli store handl increas access eas use
need demonstr valu healthcar
new drug becom advanc molecular-bas therapi requir
detail understand life scienc compani look sophist outcom
research data analyt mani physician longer make decis regard prescript
isol rather base guidanc rule payer idn govern
new system new expens drug like receiv increas scrutini iqvia
believ well posit capit new trend healthcar industri includ
increas util data assess opportun drive commerci support
defend valu new medicin help improv effici within client oper
prove valu clinic trial
parexel biopharmaceut statist sourcebook
sourcebook parexel highlight variou trend view favor
cro market first early-stag develop late stage
develop work outsourc primarili lead small pharma howev
encourag see larg pharma compani approach util outsourc
late stage discoveri stage total work outsourc time
view potenti opportun iqvia move forward
world-wide activ pipelin grow significantli highlight pre-clin drug
support comment parexel suggest strong increas overal
pipelin growth drug phase i-iii clinic trial appear slightli lower
number drug preclin develop grown rather significantli sinc number
drug preclin develop increas compound-annual-growth-rate compar phase
phase ii phase like strong growth number
drug preclin develop believ move forward larger percent
begin make way clinic trial phase furthermor believ strong
growth phase trial sign increas effici smarter decis earlier
develop process overal believ number project pipelin continu
figur world-wide pipelin continu grow
drive quicker site cycl time repeat new site compar sponsor
cro proven abl drive quicker overal site cycl time includ total week
site identif site select studi start measur done repeat site
well new site appear much effici process accord
parexel total cycl time repeat site averag week cro compar
week sponsor similarli use new site total cycl time cro averag
week compar week sponsor view differ signific
demand driver clearli abl drive effici process attempt
drive overal develop process timelin
activ project developmentpreclinicalphas inc
figur cro drive signific valu cycl time compar sponsor
excel databas build phase ii clinic trial also show
valu come build studi databas phase ii clinic trial averag
build time day well ahead averag other includ sponsor
figur cro excel quickli build releas studi databas ph ii/iii
invest highlight growth driver
iqvia highlight four strategi achiev growth
first innov leverag inform analyt transform technolog
domain expertis compani vast databas inform knowledg track
market inform treatment outcom million non-
identifi patient iqvia look optim clinic trial process enabl client
reduc cost move product market quickli effect effici process
process site select patient recruit well new innov
includ synthet control arm improv integr vast data
depositori iqvia coretm platform allow custom better util exist data
support futur develop treatment
second build extens relationship client
countri throughout world iqvia broad market focu research develop
commerci oper exist relationship continu grow iqvia abl
benefit expand agreement increas penetr continu creat new
offer enhanc alreadi offer
third growth driver expans portfolio acquisit iqvia
establish intern capabl focus sourc evalu integr acquisit
increas valu stockhold compani expect grow opportun come
acquisit landscap natur healthcar industri evolv focu life
scienc payer provid sector believ compani continu interest
willing grow acquisit offer opportun expand busi
 time maintain market share area establish
final expand penetr offer broader hc marketplac compani
grow develop offer access data look expand
penetr exist market focu integr broader healthcar cross-sect
view posit iqvia believ posit data asset
signific competit advantag industri capit chang dynam
iqvia built strong reput market leader
mention number complex clinic trial increas
increas number on-going trial complex process number novel drug
approv signific step prior year encourag see
increas novel drug approv expect trend continu although
nda approv date appear fit
histor trend nda approv april encourag
see increas past two year expect continu trial becom
streamlin third- parti vendor
iqvia experienc grow custom base number compani activ
pipelin continu grow januari number compani activ
pipelin increas compound-annual-growth-rate per pharmaproject like
continu growth iqvia potenti client base well growth total pipelin
time period increas compound-annual-growth-rate encourag
see number potenti custom continu grow along total activ
figur activ pipelin grow
pharma margin lead way healthcar industri use data compil
nyu januari see pharma biotech compani well term
gross oper ebtida margin compar sector healthcar space iqvia
sell sector rel high margin see posit
figur pharma margin strong
overal like pharma biotech market margin excel number
compani market product develop appear rise doesnt
appear slow-down effort iqvia target market
util big data commerci leader total petabyt data iqvia data
record util key drive growth focu speed intellig
healthcar data cloud look provid integr intellig inform custom
stage rang research discoveri advers event track post commerci
clinic commerci data enter system everi hour everi day
differ event record differ patient differ site trial begin
site go live patient expect amount data avail iqvia continu
grow becom use investor day novemb compani
suggest petabyt data wherea file compani suggest
petabyt one year amount store data increas drastic potenti
expect big data becom increasingli import move forward
believ extens measur taken continu handl data effici manner
figur data applic span entir drug life cycl
real-world intellig rwi creat common understand rwi key area
focu iqvia sinc compani creat novemb investor day
present iqvia highlight work top pharmaceut
compani rwi studi eu regulatori safeti studi use secondari data
time iqvia suggest pharma move cloud rwi suggest
strong growth market segment growth rwi expect driven client demand
regulatori push technology/inform enabl move forward believ benefit
iqvia strong presenc area
believ iqvia hundr million non-identifi patient record hundr
thousand data feed posit well capit industri movement toward
increas util real world data compani alreadi well establish within top
compani pharmaceut industri expect continu penetr establish
base well grow custom base
figur rwi compel opportun healthcar
iqvia seen earli success one newest product orchestr custom
engag oce oce platform iqvia invest custom relationship
manag connect sale market medic function help life scienc
compani transform model platform support custom face role sale
medic scienc liaison msl key account manag kam next level technolog
beyond typic solut oce built specif life scienc industri
best-in-class platform salesforc platform serv part commerci
ecosystem enabl end-to-end process manag relat custom engag
figur oce integr iqvia platform
oce launch decemb alreadi competit win includ larg
pharma compani roch rog-ch nr novo nordisk noco b-dk nr
alreadi user oce platform countri encourag
earli success iqvia oce previou solut appear
outdat market new solut gain traction secur larg win
show compet effect marketplac believ competit intens
come compet compani like veeva op nr
believ iqvia data asset integr applic factor
consider mani custom could ultim lead share gain
iqvia routin perform tuck-in acquisit sinc may iqvia engag
number acquisit includ legaci quintil im well one busi sale
accord factset mani acquisit undisclos amount lead us
believ mainli tuck-in allow compani gain access market
improv overal offer custom
iqvia product offer includ hundr servic applic platform solut
focus improv decis make client offer divid three main
segment technolog analyt solut research develop solut contract
technolog analyt
healthcar compani use iqvia rang cloud-bas applic
associ implement servic manag optim execut clinic
commerci strategi way orchestr well compliant
proprietari algorithm iqvia combin country-level data expertis knowledg
countri creat global market insight famili offer offer use
larg pharmaceut compani includ mida analyt link diseas insight
provid custom insight dynam differ intern market specif
target offer includ clinic trial design plan site start-up patient
compens territori align roster manag call plan complianc safeti
report master data manag
real-world insight iqvia help custom across entir healthcar spectrum includ
payer provid govern biopharmaceut answer question critic safeti
efficaci valu regard patient outcom increas demand faster
insight evid iqvia meet appli digit technolog scientif expertis
machin learn expand depositori clinic data patient privaci
secur safeguard non-identifi patient level claim prescript electron medic
acquir bi medic kk cro businessjapannew growth opportun cso businessengag dispatch medic repres pharma acquir linguamat ltduken provid text mine servic acquir medineo srlmoderna itlayenh busi portfolio research observ studi patient acquir advanc media llcusaexpand consult servic oper pharma compani e-contract e-slid librari data manag logist contract financi manag acquir solut incusaspeci data analyt life scienc acquir pilgrim qualiti solutionsusamanag softwar solut technic support profession train valid technolog acquir encor resourc llc quintil imsusa inform analyt technolog servic advisori applic manag emeasur analyt data acquir cote orphan llcusaful servic regulatori group focus orphan drug includ fda/ema orphan design strateg review ind file nda bla acquir alphaimpactrxusaprovid research base insight analyt solut biopharma consum health med devic acquir clio scienc cotokyo japandevelop pharma product cro japan acquir diversinet corpcanadaprovid secur mobil technolog connect health transact histori ia hold inc
record genom social media data use drive insight answer question
analyt consult servic iqvia offer strateg implement consult
servic servic includ advanc analyt commerci outsourc assist
commerci oper life scienc compani offer help compani improv
oper model engag healthcar stakehold effici manner
reduc overal oper cost result improv oper busi iqvia also
focus function address challeng encount drug develop
process local market knowledg deep expertis differ scientif therapeut
area global inform resourc
nation inform offer nation inform offer uniqu servic iqvia
offer countri offer consist countri level perform regard
pharmaceut sale prescript trend medic treatment promot activ throughout
multipl channel includ retail hospit mail order addit solut
extens use invest financi sector deal life scienc compani
sub-nat inform offer sub-nat inform offer uniqu servic
offer countri provid consist measur sale prescript
activ multipl level rang region individu prescrib depend countri
regul major pharmaceut sale organ use solut set goal
determin resourc measur perform calcul compens
profession countri provid overview healthcar practition
critic client commerci success regard market sale initi
research develop solut
project manag clinic monitor iqvia solut servic look achiev
effici conduct coordin multi-sit clinic trial experi databas
relationship highli train staff compani look util abil reduc data
collect step time offer includ protocol design feasibl
oper plan site start patient recruit clinic site monitor
clinic trial support servic iqvia offer rang function servic consult
support custom clinic trial requir multipl concurr servic data
stream special expertis abl help client collect analyz report
data evid need gain approv
solut solut refer joint ventur quest diagnost incorpor
togeth compani offer client end-to-end genom bioanalyt clinic trial lab
strateg plan design consult servic offer help improv decision-
make perform portfolio program protocol plan design biomark
consult benefit-risk manag regulatori affair biostatist model simul
person medicin
virtual trial proprietari inform asset technolog iqvia aim bring
trial patient end goal increas particip improv overal cycl
time effici process industry-lead clinic capabl compani
help custom reach patient popul otherwis unreach
contract sale medic solut
healthcar provid engag servic iqvia work biopharmaceut
life scienc provid custom develop deploy stakehold engag solut
includ contract sale market access profession focus drive valu
product brand stage throughout life-cycle start origin entri patent
patient engag servic iqvia nurse-bas program aim improv patient
understand diseas medic intervent non-intervent
method combin insight clinic trial social listen behavior design
person innov multichannel interact togeth act extens
prescrib treatment cours end goal patient engag servic offer
improv patient adher drive better outcom improv result reput
medic affair servic iqvia help biopharmaceut compani plan transit
clinic trial mindset commerci rang scientif strategi medic affair
servic deploy educ site acceler recruit improv retent assist
translat complex clinic trial data compel platform strategi provid field
team help facilit engag key opinion leader healthcar decis maker
product approv
iqvia individu solut divid five main categori
research develop
within research develop solut aim integr data scienc human scienc
iqvia look address grow complex challeng involv clinic research
current serv client studi global iqvia coretm assist
custom optim site predict reduc trial time faster start-up
enrol protocol assess amend commerci forecast patient safeti
figur iqvia coretm span entireti drug develop
specif area research develop solut focu includ
relationship network
real-world valu outcom
real-world valu outcom focus four specif step help custom achiev
full potenti iqvia look improv gener evid util new way use
data deliv real-world insight new data evid compani aim build
scalabl infrastructur enhanc servic offer custom focu
enhanc collabor among payer provid ensur patient reap maximum
benefit final custom abl improv commerci roll-out process
gather data offer insight
figur real-world valu outcom look improv process multipl
focu area real-world valu outcom
enterpris technolog analyt
privaci preserv data
launch perform patient
commerci offer focu improv custom precis speed deep
insight analyt iqvia tool proven offer effici launch strategi engag
strategi market access plan market develop inform offer outsourc
abil help custom streamlin certain oper reduc overal cost drive
improv effici well on-demand analyt offer real-tim visibl post launch
figur iqvia drive commerci effort rang offer
brand promot analysi
healthcar profession
brand strategi manag
launch strategi manag
complianc process design
optim forecast
patient product distribut
sale forc market
forecast franchis strategi
aim integr data analyt healthcar expertis drive improv
enterpris connect collabor result custom experi process
effici improv product quicker decis make offer built
differ platform includ salesforc mulesoft reltio combin dispar data
sourc custom environ workflow offer
capabl iqvia ensur custom right inform time manner
allow quick accur decis make custom
specif offer area includ
clinic trial design plan
perform manag
pharmacovigil autom
predict prescript
remot e-detail
payment
start-up engag
iqvia abl offer custom therapeut expertis answer relev question
data depositori experi area iqvia abl access connect
leverag data technolog analyt precis solut therapeut area
inform help custom answer question regard impact treatment
cell gene therapi differ patient group navig reimburs
strategi chang base therapeut area potenti machin learn
specif focu area includ
im health quintil merger equal first announc
later complet deal inform compar deal found tabl
deal first announc calcul price share offer
discount im health stock price previou close believ rel valu
deal achiev contributor iqvia strong stock perform late
combin entiti sacrific signific amount valu prepar compani
growth move forward im health retain total share newco
quintil sharehold held share
post-merg im health ceo bousbib retain ceo posit new compani
cfo mike mcdonnel remain quintil karl guenault remain im
follow complet deal new compani expect annual cost save
run rate bp revenu synergi exit year three expect cash tax
save would addit deal expect accret
compani earn view favor given complex associ
combin two rather larg compani
compar transact standpoint compani around mean valuat
im health slightli higher valuat quintil howev view driven
signific level debt overal combin two compani gener
sustain leverag level histor cro deal although much smaller valu merger
averag ttm ev/sal ratio ev/ebtida given respect
valuat quintil im view combin favor valuat standpoint
encourag growth display sinc deal
quintilesim newco edilut share stock price price cap stock price dilut share im adj ownership ev/adj dilut ownership newco compani file factset svb leerink estimatesquintilesim newcodilut share stock price price cap stock price dilut share im adj ownership ev/adj dilut ownership newco compani file factset svb leerink estim inc
iqvia posit among competit industri
given iqvia strong geograph reach breadth compet divers set
busi technolog analyt space
competit vast iqvia posit
accord present iqvia top vendor term softwar
spend life scienc industri see histor cro like
iqvia gain momentum among softwar provid industri
believ show commit grow technolog presenc compani
continu pair solut signific amount data believ
abl offer stronger value-add custom rel pure softwar
competitor industri iqvia recent expand softwar offer orchestr
custom engag oce view direct competitor veeva solut
compani continu grow offer believ competit industri continu
increas
histor cro transact ttm basi metricsacquirortargetannouncedd valu mm ev/salesev/ebitdasuccess failur incjunip group copra researchkendl river labswuxi capit managementpra river labsinveresk research pharmaceuticalsiguard plcmedev group research groupclintri factset averag median exclud fail deal inc
figur iqvia top softwar vendor
accord deloitt global life scienc outlook see multipl trend
benefit iqvia deloitt highlight transform technolog recent report includ
artifici intellig ai internet medic thing iomt softwar medic devic
samd blockchain do-it-yourself diagnost virtual care futur mobil expect ai
continu grow relev life scienc industri specif relat diagnosi
treatment plan monitor discoveri given iqvia strong presenc life scienc
industri see one leader drive ai advanc move forward
also encourag report highlight iomt valu
expect rise furthermor patient becom activ
health samd softwar medic devic occasion outperform clinician
diagnosi signific amount data iqvia believ well posit
futur develop softwar applic design identifi risk patient
offer accur diagnosi suggest potenti treatment
deloitt classifi data currenc life scienc innov grow amount
import data mobil becom key data help clinic trial becom less
burdensom engag optim patient care deliveri process trial
report suggest mani half trial may done virtual distant
futur new regulatori guidanc meant expedit adapt trial allow
research evalu multipl aspect singl trial better util data trial
abl measur valu appropri result better overal outcom furthermor
increas emphasi real-world evid expect increas focu end-to-end
solut deloitt see way shape strateg data partnership believ
increas import usabl data benefici iqvia base relationship
alreadi establish abil enter new relationship give
data sourc turn around util scale
expect increas competit larg tech compani base
attract industri given estim pharmaceut industri
appear gain interest among largest technolog compani world
well start-up compani deloitt suggest threaten statu quo
start-up compani focu gene-bas therapeut solut top
tech compani world begun diversifi life scienc
brightest mind immeasur data compani begin develop
diagnost therapeut understand end consum drive
improv overal experi see increas competit posit
overal industri believ lead better solut drive improv
effect treatment across entir continuum care increas competit
may headwind iqvia believ strong relationship lead market posit
benefici long run continu drive cost effect improv
top clinic trial manag compani solut outsourc partner
oper cloud licens hardwar servic industri cloud
licens market sell deliv applic platform infrastructur
custom hardwar segment includ hardwar product relat softwar oracl
life scienc solut cover clinic data manag develop oper use
help global clinic organ maintain central manag databas offer
user relev inform one main legaci provid product
servic total nearli revenu year-end may
come cloud servic licens support name recognit brand
market leader life scienc field capit abil acquir way
medidata mdso mp histor focus life scienc cloud-bas solut provid
aim improv clinic develop process process includ concept conclus
research optim develop invest technolog built offer
unifi platform pioneer analyt clinic technolog pharmaceut biotech
medic devic compani fiscal year-end decemb revenu medidata
smaller grow compani increas sale around annual past
three year ebit ebitda margin stabil around respect
medidata edg platform offer solut edg cloud
nine year program integr medidata solut provid real time view
progress accord medidata websit edg ctm increas visit report
product upward drive oper cost allow greater focu
suppli medic code safeti report health capabl work
cornerston medidata clinic cloud addit medidata recent expand
commerci side acquisit shyft analyt shyft provid real world data
offer medidata entranc commerci process optim strategi
parexel provid support servic biopharmaceut compani phase i-iv clinic
research regulatori consult market access parexel acquir june
approxim pamplona capit manag prior acquisit parexel
revenu growth flatten rang parexel
solut span entir clinic trial process differ applic stage allow
custom process trial applic intend size scope
abl harmon process protocol acceler time market minim risk last
phase failur parexel cloud-bas edc provid custom quick effici
deploy total flexibl applic focus resourc need
defin sophist sourc data verif plan
care patient id applic product clinic conductor design
accommod regulatori complianc enhanc clinic research oper type
research organ focus financ recruit particip deliveri result
monitor notif applic also integr edc solut allow
seamless sync abil push info back forth real time one applic
bio-optron announc invest januari mainsail partner
duo goal partner effect scale busi quickli possibl given
avail money intend invest heavili product custom success
grow clinic conductor product number complex clinic trial rise
datatrak develop provis electron clinic solut offer train support
host servic datatrak ctm product modern enterpris trial manag system
offer cloud base saa solut lessen amount time need implement
elimin need expens hardwar applic allow standard import
patient personnel product site vendor deviat directli platform
edc applic offer user complet control easi use interfac support specif
need trial trial basi platform scalabl trial continu grow abl
match protocol datatrak howev lose share revenu
declin year end decemb consist low ebit
ebitda margin
veeva provid industri specif cloud base softwar solut life scienc compani
product line cover complet end end process initi file clinic trial
veeva vault field medic market sale veeva vault edc allow
custom run custom trial way best fit need studi deploy
week instead month abil amend fli without downtim veeva revenu
growth declin steadili high one year ipo
recent year-end howev show sign stabil oper margin stabil
around well veeva rather new space method roll
product ensur earli win util client base well note
opportun among life scienc custom satisfi current softwar
lack recent innov
healthcar industri second total spend world-wide although
second spend behind comput electron healthcar well
ahead larg industri auto softwar industri chemic believ
signific level spend continu drive growth market compani like iqvia
well competit iqvia standpoint howev solut
wherea offer outsourc pharmaceut compani use vendor
industri medidata veeva believ offer iqvia competit advantag
among end-market help build reput retain current attract new
custom move forward expect iqvia continu build offer base
need end-market expect increas competit given attract spend among
end market seen recent larg tech compani
outsourc shift strateg relationship base model accord
deloitt report outsourc relationship focus biolog data-driven innov
capac compani industri iqvia capit expertis
artifici intellig autom cloud comput capabl model becom
data driven cro standpoint compani abl offer manufactur
data resourc might avail expens
hous report suggest one third develop stage launch
manufactur done hous cro relationship becom crucial
industri growth expect cro util continu increas compani
drug pipelin ever relationship aim reduc
overal cost process gener best possibl commerci success
compani keep process hous risk compet
manufactur util expertis view headwind
technolog advanc mention part technolog
analyt key iqvia maintain cro posit compani enter
space includ world largest tech compani iqvia need continu
develop state art applic continu prove use cro
custom believ competit industri benefici iqvia long run
term new improv technolog
iqvia compet hous univers teach hospit
pharmaceut product develop inc syneoshealth
believ major competit iqvia face research develop segment
come also note inher competit individu manufactur
vendor may use solut veeva medidata also list
competitor technolog analyt segment compani
contract offer life scienc compani
covanc contract research organ drug develop compani offer
focu research optim analysi safeti test assess consult
partner clinic develop test commerci manufactur support
compani base unit state found covanc drug
develop busi laboratori corpor america hold labcorp make
largest cro world accord explor biotech link base total labcorp revenu
labcorp acquir covanc creat world lead healthcar diagnost
compani combin clinic laboratori servic end-to-end solut
develop commerci drug diagnost
icon rank explor biotech top ten rank first compani base
unit state list compani base dublin ireland offer custom rang
servic includ consult develop commerci countri
global network icon total nearli revenu total
icon recent acquir molecularmd bolster laboratori offer molecular
diagnost test immunohistochemistri furthermor compani presenc
apac region sinc laram sinc suggest earli represent two
area expect key growth industri
parexel intern corp explor biotech list
rank explor biotech top ten list global cro provid
custom drug develop laboratori life-cycle manag servic offer
monitor regulatori data manag real-world outcom other
employe offic countri partner pharma biotech
medic devic compani well academ govern organ throughout
world compani acquir affili carlyl group hellman friedman
cash transact valu recent recapit includ two
largest cro explor biotech top cro list base
north carolina provid clinic research data solut custom
outsourc servic avail pharmaceut biotechnolog compani global
includ clinic research clinic trial servic data analyt technolog solut real world
insight revenu compani expand
offer geograph reach
final competitor iqvia specifi syneoshealth largest cro accord explor
syneo formerli inventiv research inc research also base north carolina
offer integr end-to-end solut focus develop commerci
clinic therapi clinic offer focu develop servic span trial phase
includ global studi differ unbundl servic offer clinic monitor
investig recruit data manag studi start-up commerci standpoint
compani provid servic outsourc field sell solut medic adher
commun consult servic revenu significantli
result acquisit combin inc research inventiv health
figur explor biotech top
provid addit inform mention theme
growth via acquisit smaller grow interest util real world
evid drive addit synergi
figur top detail
also see covanc labcorp cro well penetr entir market
provid initi research model usual mice test subject offer servic
extend throughout entir discoveri clinic commerci process like iqvia
center clinic commerci side histor
focu cumul data asset offer opportun continu
expand area
chart show differ featur solut servic
strongest green shade indic strength
brownish shade show believ cro may presenc gener
compani may case view particularli strong area
top focuscommentslabcorpnc usaown covanc nonclin clinic commercializationacquir top cro chiltern oncolog org bring cancer patient innov medicin fasterwork top best sell drug avail todayiqvianc usaphas i-iv clinic trial associ lab analyt servicesend-to-end clinic commerci servicelargest cro world organ growth smaller specialist acquisitionsstrong grow rwe presencesyneosnc usaend-to-end solut develop commercializationbiopharmaceut accler model connect clinic commerci bring valu small mid larg size customersparexelma usaconduct clinic trialsexpand lower cost emerg marketspartnership develop china shyft real-world data studiesbought pe firm pamplona bolster profit margin increas qualitypra health sciencesnc usaclin research data solut outsourcingacquir kkr brought public control compani specif focu singapor china region sectorsnam best cro asia biopharm asia countriespharmaceut product develop nc usaintegr drug develop lab life-cycle managementacquir evidera real world evidenceacquir synexu patient recruit copmani id patient first deliv sitecharl river labsma usamainli pre-clin focusedlead pre-clin developmentpartn hc center ventur capit firm earli introduct biotechsha research models/servic marketicon public limit corporationdublin irelandconsult develop commerci servicespartnership genom england watsonrec acquir ichom genom england molecularmdacquir mapi group french late stage cro boost rwewuxi apptecshanghai chinar manufactur sm molecul biolog cell/gen therapi devic andmolecular segment cover broad spectrum industri small molecul biolog gene/cel base therapi medic devic genom molecular diagnosticsbas rapidli grow china focu major pace hold incoh usadrug develop medic devicesmids invest intern drive businessintim cohes offic cultur organ growthpotenti acquisit targetsourc compani document/websit inc
figur explor biotech top
contract sale medic solut primarili compet in-hous sale
market depart sale servic organ consult firm
segment smallest contributor iqvia total revenu declin
see valu add continu relationship custom main competitor unit
state syneo health publici unit drug plc intern competit
singl countri region focus provid syneo unit drug plc ep corpor
co ltd
medacorp kol highlight integr market lead
spoke three medacorp kol varieti background regard iqvia solut
combin kol fairli wide rang experi work iqvia one
specialist spoke consult quintil anoth specialist work health plan
use im data value-bas care predict analyt solut anoth work
medidata life-sci role interact fairli frequent iqvia technolog
solut servic consult feedback gener good believ
merger quintil good thing long-term demand growth
kol comment encourag posit outlook move forward
come away convers medacorp kol posit iqvia seem like
merger im health quintil view favor industri expect iqvia
continu gain market share develop applic abl offer
servic believ market like integr opportun wide use legaci
im data quintil offer like continu drive valu move
futur overal iqvia cover larg base life scienc industri drug develop
process view well posit drive addit valu current potenti
top modelsdiscoveri serviceschemistrybioanalysistoxicologyimagingphas iphas iiphas iiiphas ivcommerci serviceslabcorp covanc iqviasyneosparexelpra health sciencespharmaceut product develop charl river labsicon public limit corporationwuxi apptecmedpac hold inc iqvia hold inc
first kol posit iqvia prospect
first kol spoke healthcar industri sinc earli
spent time payor provid side throughout career start three softwar
compani first ventur fund later sold though kol work
iqvia sinc merger experi work legaci im health
one kol experienc legaci im health commend integr suggest
organ work consult would use data statist capabl
im offer make well-inform clinic decis data would use predict
would like patient given condit like pharmaceut option would
kol suggest organ consult alway continu
relationship iqvia didnt seem like dissatisfi suggest
plan hospit like respect im suggest strong technic
reput around long time highli regul industri softwar
iqvia stay power one kol comment strong reput im built
industri differ other suggest mani technolog
compani lot thing mani success time given strict
regul market believ legaci im domin market
abl maintain high level data integr technolog view highli
industri mention era patient go appoint
inform ever via internet search expect flawless inform treatment im
abl keep trend kol believ continu signific
driver go forward kol suggest healthcar organ typic select
one data provid contract order limit cost switch rather expens
rel rare given iqvia strong reput data side thank im reput
long histori believ continu leader market one deepest
best design data repositori market maintain competit price
accur properli de-identifi data
merger quintil im health make incred amount sens
accord one kol suggest abil combin data straight clinic trial
data network im someth help drive market demand equiti
improv suggest wealth good data come clinic
trial go multipl year data becom plenti meaning
push back environ analyt capabl im
second kol comment technolog aspect encourag
second kol spoke experi manag consult work directli
legaci im health work mani venture-back start-up recent work
medidata work product integr kol abl offer valuabl
inform regard im health quintil well opinion transact
whole see compani move forward compet market
im quintil combin absolut posit kol suggest
time medidata spent lot time custom realiz repres
speak realli vendor manag compani relationship
mani vendor lot time spent actual manag relationship ensur
everyth go plan suggest compani difficult justifi invest
signific amount money relationship manag coordin follow
transact custom option combin number vendor iqvia
integr technolog servic offer allow easi inform flow less expens
effici compani abl better alloc resourc
mani product like still built kol referenc iqvia
signific potenti add valu broad reach mani applic
technolog still built enhanc believ combin make lot
sens strong sale pitch execut though still work done
suggest iqvia piec full suit compar clinic offer like
medidata still much imagin iqvia roll-out new technolog
applic kol believ initi focu real-world evid capit
differenti offer provid leverag quintil im busi iqvia
potenti provid integr solut enhanc commun abil cost
synergi good tech solut make sens life scienc perspect
real-world evid bring revenu compani iqvia uniqu scenario
mani organ purchas data one best offer
market data extrem valuabl custom use number reason
though util data custom accord kol iqvia would
abl add valu creat feedback loop commerci clinic view filter back
granular data result easier coordin suggest rwe work hand hand
patient report outcom creat insight data analysi use custom
believ amount data util rwe offer huge competit
advantag platform
orchestr custom engag solut make sens lead share gain
kol consid salesforc manag believ iqvia oce solut
final part integr offer believ oce solut differenti
marketplac opportun integr im data rwe offer strong
competit advantag crm marketplac oce product appear offer
strong valu proposit custom howev kol note expens switch cost given
veeva strong presenc among largest pharmaceut compani world believ
share gain market difficult win
iqvia like experi share growth vs competit kol believ
infrastructur industri still grow peopl still work paper
compani alloc money tech like continu favor
kol suggest data scientist would much like work compani like iqvia
compar pharmaceut compani base locat opportun result
pharmaceut compani would receiv better inform technolog servic outsourc
cro higher qualiti data scientist competit standpoint kol believ
tri respond dynam market industri wait share
taken opportun aris
third kol legaci quintil consult experi
third kol spoke long histori consult healthcar life scienc
industri includ time fda review chemist kol left fda mention
drug develop industri start util ex-fda employe opportun improv
process submiss
kol field multipl quintil assign consult though never
fte quintil work multipl project includ one last month
consid fte suggest compani take nimbl approach
hire consult rather full time employe locat allow quintil limit fte
turnov site finish would histor wind lay peopl hire
consult rather establish full team compani abl agil use
repeat consult possibl limit start time
quintil strong regulatori presenc kol spoke highlight multipl
regulatori solut quintil excel first would perform applic write review
regulatori assist compani prepar submit document fda
ensur properli fill use correct languag second would perform
mock pre-approv inspect ensur site prepar receiv fda visit full
assist compani would occasion get troubl becom expens
time consum enter consent decre product would halt
compani incur per day fine accord kol quintil abl nomin
remedi team get compani compliant back run effici manner
order limit neg effect consent decre oftentim help prevent
compani enter decre stall start ensur proper remedi
spoke compani prior initi come away encourag futur
orchestr custom engag solut appear threat market
compani suggest larg win oce necessarili signific discount
rather due valu proposit offer compani suggest mani
pharmaceut compani work use im data anoth compani
veeva signific valu proposit abl consolid spend one
provid offer opportun lower all-in cost furthermor seem like solut
begin gain traction though still much develop
consider invest oce roch novo-nordisk come year compani
work build solut initi feedback seem posit compani highlight
roch ceo recent europ pitch solut current potenti iqvia
client like solut garner attent recognit largest
pharmaceut compani world initi feedback posit howev believ
signific invest requir overal cost switch custom specif build
roch and/or novo-nordisk need pose risk risk associ
develop believ compani experienc versatil enough develop
solut way benefit entir market move forward believ continu
opportun win share
compani suggest term cancel trial neg connot
ask larg cro custom loss recent disclos compani
suggest normal cours action clinic trial technic
lost custom normal clinic research trial move next phase
cancel review result two result loop togeth case
trial cancel compani suggest happen everi quarter everi
cro normal event
contract sale medic expect rebound ask declin
compani experienc contract sale segment compani suggest
disrupt process blame compani initi look sell busi
howev deal fell apart follow competitor disappoint earn report
led gener disrupt busi compani howev decid re-assess
make necessari chang histor busi central repres
central offic could assist custom anywher around globe compani decid
local busi allow sale rep integr countri structur busi
creat strong relationship custom disrupt employe
custom side caus declin revenu busi compani work
integr offer im data make intellig encourag
manag opt make necessari chang busi sale fell
like expect growth segment second half
iqvia leverag vast unparallel data offer fix price clinic trial develop
convers compani iqv next gener clinic develop capabl
highlight uniqu innov offer discuss compani
sound like offer may enabl compani disrupt clinic trial develop market
offer fix up-front fee tradit help implement clinic trial
make chang order part way trial typic costli offer
fix up-front fee sound like iqvia may potenti upend clinic trial
develop space allow compani offer fix fee arrang effect
leverag vast data store mani often think iqv data prescript
sale data compani walk us data team abl leverag vast data
store iqvia includ data element includ ehr pharmaci claim genom
imag chart review discharg note etc longitudin data de-identifi afford
full pictur patient includ geoloc data doctor seen wide
array data leverag data reportedli abl identifi mani doctor
patient site need trial day one uniqu view believ
offer set price promis futur chang order view abil could
import competit advantag seek expand market share across spectrum
iqvia go downstream disrupt tradit cro industri dynam part
optim around appear sight set disrupt sever market
captur share fuel futur growth accord compani cro market one
appear ripe disrupt tradit divvi market base
specif area wish special exampl would target larg pharma
custom want resourc manag anoth would want
anoth aspect larg pharma clinic trial result claim despit
mani market competit discuss sound like want
go upstream support clinic trial stage except pre-clin studi
view expans encourag help increas compani togeth
next gener fix price clinic trial develop offer may help compani win
mr bousbib serv current role sinc octob follow quintil im
merger prior serv iqvia serv chairman ceo im begin
mr bousbib spent year unit technolog corpor began
chief strategi develop offic serv variou role utc child compani
serv ceo elev compani presid utc commerci
compani oversaw global oper carrier corpor urc fire
secur utc power serv board sinc
appoint presid unit state serv presid commiss white
mr mcdonnel join quintil serv cfo global satellit servic
provid seven year also serv cfo mc capit corpor
echostar commun iqvia respons financ oper compani
creat follow merger quintil im health includ corpor account
financi plan analysi intern audit tax treasuri investor relat corpor
develop insur real estat procur function
mr guenault respons compani cloud servic end-us support enterpris
system architectur inform secur activ prior serv iqvia
serv vice-president im health held varieti technolog manag
leadership role throughout career includ cegedim respons
global depart oper effect activ
mr berkshir serv svp busi oper iqvia sinc merger
quintil im health respons drive oper excel product
improv cost manag across organ previous serv vice-president
organiz effect im health respons drive resourc
optim product initi develop deliveri commerci area
kevin knightli presid inform
mr knightli respons grow iqvia inform asset deliveri innov offer
commerci oper develop lead edg databas manag patient
engag end-us technolog solut came iqvia vice-president inform
offer im health drove deliveri precis insight market
perform measur mr knightli two decad experi im
predecessor compani serv varieti financi oper mark gener
jon resnick presid world analyt solut
mr resnick respons iqvia global rwi initi focus help healthcar
stakehold better understand patient treatment outcom cost rwi help
stakehold payer provid regul other develop appli real world data
analyt servic previous serv vice-president gm real-world evid solut
im health held variou leadership posit includ eu leader im
consult group emea leader compani price market access busi
mr staub lead world largest contract research organ divis support
power inform technolog asset support clinic expert trial design acceler
site activ patient recruit optim trial execut also serv chair
research develop solut execut committe previous mr staub serv
presid novella clinic quintil compani acquir join
novella serv presid ceo novella becam
agil result orient cro fast grow area specialti pharmaci medic
board director
ms burt serv board iqvia redm inc welldynerx inc previous serv
senior vice-president corpor financ develop inc advisor psilo group
manag llc md head-health invest bank group chase secur inc
ms goggin serv director iqvia sinc juli spent three decad
johnson johnson serv number execut oper role last ten
year serv johnson johnson execut committe world-wide chairman
consum group provid leadership fully-integr person healthcar
portfolio advisori board bayer ag member board director td
mr danhakl iqvia board sinc octob previous serv director
im februari octob current manag lgp
sinc also serv board director saver in crew
group inc petco anim suppli inc arden group inc
mr fasano serv ad director iqvia sinc octob previous director
im januari octob lead quintil merger current
manag director lead cpp invest board fund secondari co-invest
group previous led cppib princip invest group also serv board
asurion llc cequel commun hold llc new asurion corp
mr rittenmey serv director sinc octob serv director im
april previous serv chairman presid ceo expert global
solut inc june also serv chairman ceo presid
execut vice presid global servic deliveri throughout time
system corpor chairman feder american hospit execut
chairman ceo tenet health corp ceo turnberri advisor llc also serv
board inc
mr sisitski serv iqvia board director sinc octob come
im board serv sinc februari tpg lead
compani invest activ global healthcar sector also serv board
director surgic affili inc aptali hold inc iasi healthcar corp
healthscop ltd immucor inc pharmaceut compani inc
mr leonard serv director iqvia sinc octob previous serv
board quintil sinc februari mr leonard serv chief medic offic
intellia inc compani involv gene base therapi previous chief
scientif offic svp research develop abbvi inc also board
biotechnolog innov organ ifm llc
mr evanisko serv iqvia board sinc octob previous serv
director quintil sinc current chairman parx solut inc compani
provid process servic physician practic past serv execut
chairman adheri inc consult clarion healthcar consult llc m|c
mr connaughton serv director sinc octob previous serv director
quintil sinc mr connaughton manag director bain capit sinc
also serv director iheartmedica inc medic group hold inc
product laboratori grupo notr dame intermedia boston celtic
mr greenberg iqvia board sinc octob previous serv
quintil board director sinc chairman januari octob
serv chairman compani sinc formerli serv
chairman ceo mcdonald corpor respect
retir mr greenberg held variou leadership posit prior
becom ceo includ presid chairman ceo mcdonald usa also serv
director allstat corpor inc
mr coslet serv iqvia board sinc octob come quintil
serv board sinc merger senior partner tpg
chairman tpg invest committe manag committe serv
member hold manag committe mr coslet serv boar iasi
healthcar corpor petco anim suppli inc biomet inc
iqvia strong histori beat estim especi sinc merger quintil im
result reflect quintil perform prior merger result iqvia begin dec
iqvia miss revenu estim first quarter combin compani howev sinc
beaten revenu ebitda ep estim everi quarter view track record
posit includ result quintil prior merger ep still beat
time ebitda miss three time ten quarter revenu miss time ten
quarter although result stand-alon quintil slightli volatil encourag
iqvia well rel estim like surpris percent remain
rel moder instanc beat exceed surpris us
mean manag clear commun street strong
visibl busi
manag recent reiter guidanc issu guid conjunct
earn report guid suggest decent growth top
bottom line revenu guid grow y/i midpoint adjust ep
guid growth midpoint full year manag guid midpoint
revenu growth believ signal strong ramp given
growth guid growth adjust ep rang
year impli strong expect growth midpoint y/i current
estim slightli upper end guidanc three guid metric
remain slightli consensu well believ iqvia strong histori revenu ebitda
ep beat continu move forward full year model revenu ebitda
within compani guid rang expect adjust ep come guid
rang consensu
figur iqvia guidanc estim
revenu growth segment
iqvia revenu group three bucket technolog analyt research
develop contract sale medic solut prior quintil im merger
research develop primari contributor quintil howev combin
see technolog analyt segment taken signific share total result
transact like grow mix shift compani see strong
opportun growth major segment move forward
figur iqvia revenu segment
compani guidancegrowth midpointconsensussvb adj adj adj adj sourc compani document factset svb leerink inc
expect total revenu growth continu decent pace driven annual growth
technolog analyt growth research develop
see merger contribut total growth follow
normal growth rate like proposit iqvia bring tabl
believ continu grow rapidli chang expand industri howev
size broad may difficult achiev doubl digit growth long-term
said believ high singl digit growth achiev strong sign grow
attract industri fx becom tailwind doubl digit revenu growth
possibl view
figur revenu growth expect stabil
iqvia experienc declin gross margin merger howev gross margin appear
stabil rang technolog analyt contribut strongest level
gross margin around model contract due invest spend
total revenu breakdowntechnolog analyticsresearch developmentcontract sale medic sale medic compani document svb leerink estimatesrevenu growth segment iqvia hold inc
stabil around research develop experienc signific declin gross
margin follow merger believ strong gm
floor segment stabil continu level slightli higher contract
sale medic solut continu declin revenu margin model
gm expect expand slightli time
figur gross margin segment
similar gross margin see profit margin stabil total profit margin
low rang expect continu mix shift busi continu favor
technolog analyt research develop expect technolog analyt
profit margin maintain level mid rang research develop remain
low rang expect contract sale medic solut show
sale medic compani document svb leerink estimatesgross margin margin segmenttechnolog analyticsresearch developmentcontract sale medic solutionstot iqvia hold inc
figur total profit margin stabil rang
ep growth estim
expect iqvia continu drive solid ep growth adjust ep grew
model growth next three fiscal year remain low mid-teen percentag
rang believ abil achiev scale platform sell addit applic
exist client grow busi opportun exist outsourc client continu
allow adjust ep grow rate greater revenu adjust ebitda
figur adjust ep growth expect continu
sale medic compani document svb leerink estimatesprofit margin margin segmenttechnolog analyticsresearch developmentcontract sale medic adj ep iqvia hold inc
iqvia cash debt long term
short term contractu matur long-term debt
follow thereaft view
level debt signific believ iqvia well posit meet short-term
need like continu take addit debt opportun aris grow
busi believ use leverag benefici busi payment
expect increas significantli anticip addit agreement repay
made lessen blow asset iqvia larg establish
compani space
iqvia strong oper cash flow
total gener believ iqvia well posit continu drive oper cash
flow busi continu grow cash balanc like fluctuat debt
repay activ like overal balanc compani well posit drive
cash flow cover short term liabil drive perform cover matur futur
estim total capit deploy made mostli share
repurchas addit contributor capit expenditur acquisit recent
histori small tuck acquisit expect continu materi part
capit deploy strategi hundr million bar larg acquisit
figur capit deploy fuel share repurchas
given stock strong perform past year iqvia trade histor
averag believ well deserv compar comp group differ healthcar
cloud cro firm includ cmic iclr lh nr
iqvia valu averag iqvia price-to-earnings ratio slightli behind
year averag slightli ahead comp group similarli
ev/ebitda standpoint ahead comp group
next month expect share trade averag
ep estim ev/ebitda believ deserv premium rel
histori given abil continu drive growth competit industri captur
valu end market continu look innov
iqvia fair valu price-to-earnings adj fair valu ev/adj ebitda cash share ebitda sale price number million except per share datasourc compani file svb leerink llc iqvia hold inc
streetstreet ebitlatesteq epspegmarginshorttickerrat close cloud/crocm river health factset market data consensu estim close year calendar applic ebitda ep non-gaap availablenm meaning equiti valu enterpris valu base latest quarter dilut share count equiti valu market cap plu valu stock option treasuri method factset consensu earn estim base factset consensu estimatesp/ ev ebitdaev revenu iqvia hold inc
risk valuat
iqvia like becom heavili invest certain clinic trial success trial
key drive futur revenu high profil trial produc neg result
possibl compani suffer sunk cost elimin futur revenu
opportun relat commerci futur opportun compani
work
possibl mani pharmaceut biotechnolog compani iqvia
custom earli stage compani run start-up fund compani
unabl continu rais money fuel product clinic trial pre-approv
process iqvia posit market may suffer addit macro standpoint
signific market downturn could addit neg effect iqvia gener
inabl rais money market place relat individu compani product
model year deprec chang wc ex cash flow inc
possibl regul us countri updat approv process
requir new drug way drug commerci iqvia fail
react quickli chang may risk lose current potenti custom
competitor chang regul may increas difficulti process
may put addit strain smaller life scienc compani iqvia work creat
increas financi burden increas overal risk compani chang
regul clinic trial space like requir signific updat exist
applic potenti develop new applic futur regard
commerci chang regul may limit use vast amount data
iqvia util would limit potenti compani offer increas valu
custom
trial may risk compani experi shortag drug test
could result potenti loss custom expect revenu iqvia furthermor
navig drug shortag import issu compani util iqvia commerci
solut drug shortag result headwind custom possibl iqvia
potenti revenu futur relationship effect custom suffer
iqvia compet highli competit market compet
also healthcar technolog compani specif focus develop roll
applic help life scienc compani carri clinic trial addit
may use solut develop compani increas use case
solut well potenti life scienc compani use solut trial
road iqvia work develop solut
orchestr custom engag delay disrupt perform either clinic
commerci side busi may result custom attrit
iqvia unabl enrol suffici number patient custom trial
revenu stream would like risk unabl identifi enough patient like
custom would termin contract iqvia would suffer delay futur
iqvia establish one lead healthcar databas world store
data non-identifi breach may neg implic compani term
privaci well compet cloud base compani captur similar data
iqvia may leader use data reput implic would like benefit
custom furthermor data privaci law chang possibl use
data may neg impact base certain inform would like
headwind futur perform
consolid life scienc industri may limit amount servic offer
iqvia abl provid consolid may drive increas penetr individu
compani product servic offer scale basi like
product util two compani would gener revenu one compani
combin util two base initi cost structur increas level
consolid industri may threat potenti growth busi like
compani measur captur increas util per compani
iqvia gener indemnifi insur patient harm possibl
reput would suffer drug trial caus harm patient financi harm also
possibl loss revenu life scienc compani work well
potenti lawsuit may involv
iqvia custom depend produc accur relev inform time
must ensur full complianc strict chang regul failur provid
inform compli regul includ audit trail data encrypt secur access
specif industri regul may limit compani abil perform advers affect
stock price
on-going litig iqvia alleg unlaw use
intellectu properti improv promot market data offer veeva also file
countersuit alleg anticompetit behavior seek punit damag litig cost
litig potenti becom high profil process given two compani involv
major player life scienc industri end rule iqvia favor may
face financi damag well limit potenti grow futur increas
incom statement fye decemb
million
revenu
research develop solut
revenu
revenu
revenu excl
revenu
sell gener administr expens
revenu
depreci amort
revenu
revenu
loss extinguish debt
loss extinguish debt
restructur relat charg
incom non-control interest
minor interest effect non-gaap adjust
incom statement fye decemb
million
non-gaap gaap net incom reconcili
provis incom tax
depreci amort
incom loss unconsolid affili
incom non-control interest
loss extinguish debt
restructur relat charg
gaap net incom attribut inc
net incom attribut non control interest
equiti earn unconsolid affili
incom equiti earn unconsol affili
provis incom tax
incom loss unconsolid affili
incom non-control interest
loss extinguish debt
restructur relat charg
incom non-control interest
minor interest effect non-gaap adjust
gaap net incom attribut inc
add back equiti earn unconsolid affili
incom statement fye decemb
million
revenu
segment revenu
revenu mix
sell gener administr expens
segment revenu
research develop solut
revenu
segment revenu
revenu mix
sell gener administr expens
segment revenu
contract sale medic solut
revenu
segment revenu
revenu mix
sell gener administr expens
segment revenu
incom statement fye decemb
million
revenu geographi
gener corpor unalloc
gener corpor unalloc cost
total revenu
depreci amort
total revenu
total revenu
total revenu
total incom oper
million
cash equival
trade account receiv unbil servic net
invest debt equiti secur
current asset receiv
properti equip net
invest debt equiti secur
invest unconsolid affili
deposit asset
account payabl accru expens
current portion long term debt
commit conting
common stock addit paid capit
treasuri stock cost
accumul comprehens incom
equiti attribut iqvia hold inc stockhold
total liabil stockhold equiti
refer compani data use driver ratio
total cost servic
market cap
million
flow oper activ
adjust reconcil net incom net cash provid oper
depreci amort
amort debt issuanc cost discount
amort accumul comprehens loss termin interest rate swap
impair goodwil identifi intang asset
dispos properti equip net
earn unconsolid affili
loss gain invest net
benefit defer incom tax
excess incom tax benefit stock-bas award activ
chang oper asset liabil
account receiv unbil servic unearn incom
chang oper asset liabil
net cash provid use oper activ
flow invest activ
acquisit properti equip softwar
acquisit busi net cash acquir
disposit busi net cash dispos
purchas sale market secur
invest unconsolid affili net payment receiv
invest equiti servic
net cash provid invest activ
flow financ activ
proce issuanc debt
payment debt issuanc cost
repay debt
proce revolv credit facil
repay revolv credit facil
princip payment capit leas oblig
proce relat employe stock option plan
repurchas common stock
distribut non-control interest net
conting consider defer purchas price payment
excess incom tax benefit stock-bas award activ
net cash use financ activ
effect foreign currenc exchang rate chang cash
increas decreas cash cash equival
cash equival begin period
cash equival end period
oper
margin revenu
